Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 128 Breast Neoplasms 95 Colorectal Neoplasms 62 Carcinoma, Hepatocellular 59 Stomach Neoplasms 49 Squamous Cell Carcinoma of Head and Neck 47 Lung Neoplasms 44 Prostatic Neoplasms 43 Leukemia, Myeloid, Acute 43 Triple Negative Breast Neoplasms 42 Small Cell Lung Carcinoma 40 Uterine Cervical Neoplasms 37 Rectal Neoplasms 36 Pancreatic Neoplasms 31 Neoplasms 29 Neoplasm Metastasis 29 Recurrence 26 Esophageal Squamous Cell Carcinoma 25 Ovarian Neoplasms 23 Esophageal Neoplasms 23 Nasopharyngeal Carcinoma 21 Brain Neoplasms 21 Lymphoma, Large B-Cell, Diffuse 20 Colonic Neoplasms 20 Carcinoma, Renal Cell 20 Melanoma 19 Endometrial Neoplasms 19 Biliary Tract Neoplasms 18 Head and Neck Neoplasms 17 Multiple Myeloma 16

Interventions

trifluridine tipiracil drug combination 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Not yet recruiting × mCRC × Clear all

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Jinan Central Hospital

Phase 2 Not yet recruiting

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡